With no cure in sight, drugs firm LianBio begins exit strategy
The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four…
Everest reaches new heights on growing drug sales
The innovative drug maker said its revenue soared more than 850% last year to between 124 million yuan and 126 million yuan Key Takeaways: Everest Medicines’ revenue soared nine-fold last…
HBM gets health boost from drug licensing deals
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of…
CHINA BULLETIN: Europe Calls on China
In this week’s issue EU leaders come calling on China, Evergrande restructures and Airbus invests. On a scale of 1 to 10, we give the week a 5 for offshore-listed China stocks.
CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough
Drugmaker CSPC Pharma gets the green light to produce China’s first homegrown mRNA vaccine, but the breakthrough comes too late in the pandemic to impress investors Key Takeaways: News of…
Henlius Swallows Bitter Pill in Watered-Down Licensing Deal
The innovative drug company will receive less benefits from an existing licensing deal after revisions to reflect high R&D costs Key Takeaways: Henlius Biotech will receive up to $11 million…
After 2022 Slowdown, WuXi Biologics Gets Growth Medicine From Big New Order
China’s leading provider of outsourced medical services said its profit and revenue rose 48.4% and 30% last year, respectively, marking a significant slowdown from the previous yearKey Takeaways:WuXi Biologics revenue…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
-
Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
ANL.US
-
Everest reaches new heights on growing drug sales
1952.HK
